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Abstract Three widely-used GKq chimeras harboring the last
five residues of GKi, GKo and GKz (qi5, qo5 and qz5) were
examined for their ability to serve as substrates for pertussis
toxin (PTX)-catalyzed ADP-ribosylation. In COS-7 cells
coexpressing one of the three opioid receptors (W, N, and U) and
a GKq chimera, agonist-induced stimulation of phosphoinositide-
specific phospholipase C (PI-PLC) was largely insensitive to
PTX treatment. Only the qi5-mediated stimulation of PI-PLC
by U-opioids was partially inhibited by PTX. In LQ-release
assays, PTX treatment did not affect the ability of opioid
receptors to activate these chimeras. [32P]ADP-ribosylation
labeled GKi=o but not qi5 or qo5, although the expression of
these chimeras was confirmed by immunodetection. Thus, GKq
chimeras with a GKi=o-like tail are insensitive to PTX treatment.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Heterotrimeric (KLQ) G proteins transduce extracellular sig-
nals detected by speci¢c cell-surface receptors into intracellu-
lar messages. A large variety of e¡ector molecules are regu-
lated by 20 distinct G proteins which are classi¢ed into four
subfamilies (Gi, Gs, Gq and G12) based on the homologies of
their K subunits [1]. Many receptors for neurotransmitters,
hormones, neuropeptides, and photons utilize members of
the Gi subfamily for signal transduction. Seven of the eight
members in the Gi subfamily (except Gz) are substrates of
pertussis toxin (PTX).
PTX is derived from Bordetella pertussis. It is a heterohexa-
meric protein divided into A (Active) and B (Binding) subu-
nits. The A subunit possesses ADP-ribosyltransferase activity
and the B subunit, which is a pentamer, confers binding spe-
ci¢city to the enzyme. The heterohexamer catalyzes the ADP-
ribosylation of GK subunits at a cysteine residue four amino
acids from the carboxy-terminus, using NAD as the donor [2].
This covalent modi¢cation uncouples the G proteins from the
activated receptors. The speci¢city of PTX-catalyzed ADP-
ribosylation has proven extremely useful in delineating signal
transduction pathways in which the role of a G protein is
suspected [3], but this reaction depends on a number of fac-
tors. The Vmax, but not the Km of this reaction is dependent
on the association of LQ dimers to the GK subunits [4,5].
Mutational analysis at the C-terminus of GKo points to the
importance of the three penultimate amino acid residues, Cys-
Gly-Leu, in PTX-catalyzed ADP-ribosylation [6]. However,
studies with GKs=i chimeras indicate that the C-terminus
ADP acceptor site alone is not su⁄cient for PTX recognition
[7,8]. The primary structure of the N-terminus of GK, which is
in close proximity to the C-terminus [9], is also important in
PTX recognition [7].
To date, although the mechanism by which PTX recognizes
GK is not fully understood, PTX treatment has become a
widely used experimental strategy to characterize GK sub-
units. PTX-sensitive and -insensitive GK subunits are often
di¡erentiated solely on the basis of the presence of a cysteine
residue near the C-terminus [6]. Recent attempts to determine
the speci¢city and ¢delity of receptor-G protein coupling have
relied heavily on the construction of mutant as well as chi-
meric G proteins. Because of their wide spectrum of receptor
linkage, members of the Gi subfamily are often selected as
donors in the design of chimeric G proteins. A series of chi-
meras constructed between GKq and GKi, GKo, or GKz [10]
have proven to be extremely useful in delineating the speci¢c-
ity of receptor-G protein coupling [11]. Some of these GKq
chimeras contain the PTX-catalyzed ADP-ribosylation site.
Due to their widespread use in di¡erent receptor systems
[12^14], it has become important to con¢rm if these GKq
chimeras are indeed PTX-sensitive. In the present study, we
provide biochemical evidence that two such chimeras, qi5 and
qo5, are resistant to modi¢cation by PTX. Our results show
that GK chimeras containing a GKi=o like C-terminus cannot
be assumed to be PTX-sensitive.
2. Materials and methods
2.1. Materials
The cDNAs encoding the rat W-opioid, mouse N- and U-opioid re-
ceptors were generous gifts from L. Yu (University of Cincinnati
College of Medicine), C. Evans (UCLA), and G. Bell (University of
Chicago, IL, USA), respectively. The GKq chimeras (qi5, qo5, and
qz5) were kindly donated by H.R. Bourne and B. Conklin (UCSF).
Type II adenylyl cyclase (AC II) cDNA was obtained from R. Reed
(Johns Hopkins University, Baltimore, MD, USA). PTX was pur-
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chased from List Biological Laboratories (Campbell, CA, USA). The
GKq-speci¢c antiserum E-17 was obtained from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). [3H]Adenine and [3H]myo-inositol
were purchased from Amersham International (Buckinghamshire,
UK) and DuPont-NEN (Boston, MA, USA), respectively. Cell cul-
ture reagents were from Life Technologies (Grand Island, NY, USA)
and all other chemicals were purchased from Sigma (St. Louis, MO,
USA).
2.2. Cell culture and cDNA transfections
COS-7 cells (ATCC CRL-1651) were maintained in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal
calf serum (FCS), 50 units/ml penicillin and 50 Wg/ml streptomycin, at
37‡C in a humidi¢ed atmosphere containing 5% CO2. Cells were
seeded in 12-well plates at 1.2U105 cells per well 24 h before trans-
fection. Cells were transfected with various cDNAs by the DEAE-
dextran method as previously described [15]. Brie£y, Qiagen puri¢ed
cDNAs were added to growth media containing 100 nM chloroquine
and 250 Wg/ml DEAE-dextran. The cells were exposed to the trans-
fection cocktail for 3.5 h then shocked with 10% DMSO (v/v) in
phosphate bu¡ered saline (PBS) for 1 min. The cells were washed
with PBS before returning to growth media for 24 h. HEK 293 cells
(ATCC CRL-1573) were cultured in Eagle’s minimal essential medium
(MEM) with 10% FCS. 2U105 cells were transfected for 1.5 h with
400 Wg/ml of DEAE-dextran. Other conditions and procedures were
the same as with COS-7 cells.
2.3. Inositol phosphates (IP) and cAMP assays
Transfected cells were labeled with [3H]myo-inositol (2.5 WCi/ml) or
[3H]adenine (1 WCi/ml) in growth media, with or without PTX (100
ng/ml) for 18^24 h. Labeled cells were assayed for inositol phosphates
(IP) or cAMP accumulation as described previously [15,16]. Absolute
measurements of IP or cAMP accumulation varied between experi-
ments, but variability within a given experiment was generally 6 10%.
2.4. Membrane protein preparation and immunodetection of chimeric
GKq subunits
COS-7 cells were grown on 150-mm dishes to 70^80% con£uence.
Transfection was performed as in 12-well plates with proper adjust-
ments to the volumes and amounts of the reagents used. Transfected
cells were incubated with growth media at normal growth conditions
for 48 h for the expression of exogenous proteins. Membranes were
prepared from the transfected cells by one cycle of freeze-thawing
followed by 10 passages through a 27-gauge needle [17]. Protein con-
centrations were determined using the Bio-Rad Protein Assay Kit.
For each sample, 75 Wg of membrane proteins were separated on a
12.5% SDS-polyacrylamide gel and electrophoretically transferred to
nitrocellulose membranes. Protein markers on the membrane were
localized by Ponceau S staining. Immunodetection of GKq chimeras
by the GKq-speci¢c antiserum E-17 (Santa Cruz Biotechnology) was
visualized by chemiluminescence using the ECL kit from Amersham.
2.5. [32P]ADP-ribosylation
Pertussis toxin-catalyzed ADP-ribosylation of membrane-bound
proteins was performed as described previously [18]. PTX (50 Wg/
ml) was preactivated at 25‡C for 1 h in 50 mM DTT. ADP-ribosyla-
tion was carried out in 0.1 ml (¢nal volume) of 100 mM Tris-HCl (pH
7.5) containing 10 mM thymidine, 1 mM EDTA, 1 mM L-K-dimyr-
istol phosphatidylcholine, 2.5 mM MgCl2, 1 mM ATP, 50^75 Wg
protein of membranes, 25 WM [K-32P]NAD, and 5 Wg of preactivated
pertussis toxin (90 min, 25‡C). The PTX substrates were identi¢ed by
precipitating the proteins immediately after ADP-ribosylation by
chloroform/methanol and subjected to 12.5% SDS-polyacrylamide
gel electrophoresis and autoradiography. The gel was exposed to
Fuji RX ¢lm at 370‡C for 1^2 days.
3. Results and discussion
Chimeric GKq subunits containing the last few residues of
GKi or GKo [10] can link Gi-coupled receptors to the stimu-
lation of PI-PLC, and thus provide alternative means to study
ligand-receptor interactions [12] as well as determining the
¢delity of receptor-G protein coupling [11,13,14]. We have
previously demonstrated that the three opioid receptors (W,
N and U) exhibit di¡erential abilities to stimulate GKq chime-
ras (qi5, qo5 and qz5; with the last ¢ve residues altered) in
heterologous expression systems [14]. Of the three GKq chime-
ras, both qi5 and qo5 contain the PTX-catalyzed ADP-ribo-
sylation site. Despite their widespread use, it has not been
unequivocally established that qi5- and qo5-mediated re-
sponses can be abolished by PTX. If so, PTX-sensitivity might
serve as a distinguishing feature between wild-type GKq=11 and
these two GKq chimeras. A previous study with dopamine D2
receptor and qi4 (a chimera which is functionally similar to
qi5) indicated that qi4-mediated stimulation of PI-PLC is sen-
sitive to PTX whereas the qz5 response is insensitive [10]. We
investigated whether the interplay between the opioid recep-
tors and GKq chimeras are similarly a¡ected by PTX. COS-7
cells were cotransfected with cDNAs encoding the opioid re-
ceptors and the GKq chimeras. Transfected cells were treated
with or without PTX (100 ng/ml) and subsequently assayed
for IP production in response to opioid agonists. Except for
W-receptor and qo5, each pair of opioid receptor and GKq
chimera allowed opioid agonists to stimulate PI-PLC in trans-
fected COS-7 cells (Fig. 1). This is in accordance with our
previous study [14]. The agonist-induced stimulation of PI-
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Fig. 1. E¡ect of PTX treatment on IP formation in cells coexpress-
ing the opioid receptors and GKq chimeras. COS-7 cells were transi-
ently cotransfected with cDNAs (0.25 Wg/ml), encoding an opioid re-
ceptor (U, N, or W) and one of the three GKq chimeras (qi5, qo5, or
qz5) as indicated. Transfected cells were labeled with [3H]inositol in
the absence or presence of PTX (100 ng/ml) and subsequently as-
sayed for responses to the corresponding opioid agonist (U-50 488H,
DPDPE, or DAGO) at 300 nM. KOR, U-opioid receptor; DOR, N-
opioid receptor; MOR, W-opioid receptor. Results are expressed as
percent stimulation of IP production over basal response which
ranged from 10.5 þ 1.4 to 13.2 þ 4.6. Data shown are mean þ S.D. of
triplicate determinations from a typical experiment; two additional
experiments gave similar results. *, PTX signi¢cantly reduced the
ability of U-50 488 to stimulate the formation of IP with the qi5
chimera; paired Bonferroni t-test, P6 0.05.
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PLC was only slightly reduced by PTX treatment in cells
coexpressing every combination of GKq chimeras and the W-
or N-opioid receptor (Fig. 1). PTX partially inhibited (V30%)
the PI-PLC response in cells coexpressing the U-opioid recep-
tor and qi5, but not when qi5 was replaced by either qo5 or
qz5 (Fig. 1). Under similar experimental conditions, opioid-
induced inhibition of adenylyl cyclase is completely abolished
by PTX (data not shown but see [16,19,20]).
To con¢rm that the functions of qi5 and qo5 are insensitive
to PTX treatment, we assessed the ability of these chimeras to
release LQ subunits upon activation by agonist-bound opioid
receptors. In the presence of activated GKs, Gi-coupled recep-
tors are known to stimulate type II adenylyl cyclase (AC II)
through the LQ subunits released from the PTX-sensitive GKi
[16,21]. Previous studies have demonstrated that the opioid
receptors can stimulate AC II in transiently transfected
HEK 293 cells via the endogenous Gi/Go proteins [16,19,20].
To test if opioid receptors can stimulate AC II through GKq
chimeras, we cotransfected HEK 293 cells with cDNAs encod-
ing AC II, GKsRC (a mutationally activated form of GKs),
and the U-opioid receptor in the absence and presence of GKq
chimeras. We switched to HEK 293 cells because this system
has a better signal-to-noise ratio for cAMP assays. In control
cells transfected with pcDNA1 instead of a GKq chimera, U-
50 488-stimulated cAMP accumulation was completely abol-
ished by PTX treatment (Fig. 2). However, coexpression of
qi5, qo5, or qz5 with the U-opioid receptor rendered the ago-
nist-induced cAMP accumulation insensitive to PTX (Fig. 2).
Similar results were seen with the N-opioid receptor (data not
shown). The inability of PTX to prevent LQ release in these
studies suggests that, like qz5, both qi5 and qo5 are insensitive
to PTX treatment.
In order to verify the results obtained from the functional
studies, we performed immunodetection of the GKq chimeras
and PTX-catalyzed [32P]ADP-ribosylation on membranes pre-
pared from transfected cells. COS-7 cells were cotransfected
with cDNAs encoding the N-opioid receptors and the GKq
chimeras, and the transfected cells were harvested two days
later for the preparation of plasma membranes. Using a GKq-
speci¢c antiserum, we con¢rmed that qi5, qo5 and qz5 were
expressed to similar levels beyond endogenous GKq in the
transfected cells (Fig. 3). The same membranes were then
subjected to PTX-catalyzed [32P]ADP-ribosylation. Since the
GKq chimeras have a deduced molecular weight of 43 kDa,
they should be easily di¡erentiated from the endogenous PTX
substrates, GKi=o (39^41 kDa). As shown in Fig. 3, only GKi=o
subunits were [32P]ADP-ribosylated in membranes prepared
from control and GKq chimera-expressing cells. Similar results
were obtained with the U-opioid receptor and, collectively,
they indicate that qi5 and qo5 are poor substrates for PTX-
catalyzed ADP-ribosylation.
Since qz5 lacks the PTX target residue, it is not surprising
that the toxin fails to block agonist-induced activation of PI-
PLC in cells coexpressing qz5. However, the almost complete
lack of PTX-sensitivity of qi5- and qo5-mediated PI-PLC
stimulation is enticing. The cysteine and glycine residues at
34 and 33 positions of the carboxy-terminal are important
for ADP-ribosylation by PTX [6]. As the qi5 and qo5 chime-
ras contain these residues, they should be ADP-ribosylated,
whereas the absence of cysteine makes the qz5 chimera PTX-
insensitive. Although it has previously been demonstrated that
a GKq chimera, the qi4, is sensitive to PTX [10], inhibition of
the qi4-mediated response by the toxin was incomplete. In
fact, the coupling of dopamine D2 receptor to qi4 is only
partially (V50%) inhibited by PTX [10]. Thus our results
are in line with the previous ¢ndings. Moreover, studies
with GKs=i chimeras indicate that the C-terminus ADP accept-
or site alone is not su⁄cient for PTX recognition [8,9]. Given
that the PTX binding regions on GKi=o may be similar, if not
identical, to those required for interaction with receptors, it is
reasonable to assume that the PTX contact sites involve more
than just the last ¢ve residues of the GK subunit. The N-
terminus of the GK subunit is known to interact with recep-
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Fig. 2. U-50 488-induced stimulation of AC II by the GKq chimeras.
HEK 293 cells were cotransfected with AC II (0.25 Wg/ml), U-opioid
receptor (0.25 Wg/ml), KsRC (0.025 Wg/ml), and 0.25 Wg/ml of the
pcDNAI vector as a control or one of the GKq chimeras (qi5, qo5,
or qz5). Cells were labeled with [3H]adenine, with or without PTX
(100 ng/ml) and assayed for cAMP accumulation in response to 300
nM U-50 488. Results are expressed as percent stimulation of cAMP
formation in the presence of U-50 488, compared with that meas-
ured in the absence of the agonist. The basal value varied between
1.3 þ 0.1 to 3.5 þ 0.1. Data represent triplicate determinations in a
single experiment; two independent experiments gave similar results.
*, PTX signi¢cantly reduced the ability of U-50 488 to activate AC
II; paired Bonferroni t-test, P6 0.05.
Fig. 3. [32P]ADP-ribosylation and immunodetection. COS-7 cells
were cotransfected with cDNA encoding the N-opioid receptor with-
out (DOR) or with one of the GKq chimeras qi5, qo5 or qz5. Mem-
branes were prepared from the transfected cells as described in Sec-
tion 2. The G proteins in membranes from these COS-7 cells were
separated by 12.5% SDS-polyacrylamide gel electrophoresis and de-
tected by immunoblotting with a GKq-speci¢c antiserum (upper pan-
el). The membranes were also subjected to [32P]ADP-ribosylation
with PTX. [32P]ADP-ribosylated substrates were resolved on a
12.5% SDS-polyacrylamide gel and visualized by autoradiography
(lower panel). Arrowheads indicate the relative positions of GKq
chimeras and GKi=o proteins.
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tors and LQ subunits [22]. It should also be noted that the U-
opioid induced stimulation of PI-PLC mediated via qi5 was
partially sensitive to PTX. Slight di¡erences in the PTX-sen-
sitivities of qo5 and qi5 might be explained in terms of the
intrinsic properties of Gi and Go as substrates for PTX-cata-
lyzed ADP-ribosylations. Puri¢ed Gi is more sensitive to
ADP-ribosylation by PTX than Go [23]. Taken together, the
present study demonstrated that GKq chimeras containing
GKi=o-like C-terminus are poor substrates of PTX. The
PTX-insensitivity of qi5 and qo5 can be used to distinguish
their responses from endogenous Gi proteins, and thus further
broadens their usage in characterizing Gi-coupled receptors.
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